Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap
Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies that could help oncology and immunology patients. Their pipeline has 3 interesting Phase 1 candidates for SLE, Solid Tumors, and B-cell lymphoma. But in my view, FT819 shows the most promising, as they recently achieved remission for one SLE patient.
Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
Fate Therapeutics, Inc. reported positive phase 1 data for FT819 in treating moderate-to-severe Systemic Lupus Erythematosus, showing remission in one patient with fludarabine-free conditioning. A second study arm will test FT819 as an add-on to maintenance therapy without conditioning chemotherapy targeting SLE patients. Data from the first three patients will be presented at the American Society of Hematology Annual Meeting, being held between December 7th through 10th of 2024.
FATE Presents Encourgaing Data From Lupus Study, Stock Gains
Fate Therapeutics presents promising data on FT819 showing the first patient treated experienced a favorable clinical experience, achieved drug-free clinical remission, and continues on-study.
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus
FATE reports a narrower-than-expected loss on higher revenues for the third quarter of 2024. The company's innovative pipeline is in focus.
Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.46 per share a year ago.
Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy
Fate Therapeutics (FATE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow
FATE reports a lower-than-expected loss on higher revenues and lower operating expenses in the second quarter of 2024.
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.54 per share a year ago.
Russell Investments Group Ltd. Acquires 59,267 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)
Russell Investments Group Ltd. increased its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 34.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 233,748 shares of the biopharmaceutical company’s stock after purchasing an additional 59,267 shares during the period. Russell Investments Group Ltd. owned 0.24% of Fate Therapeutics worth $874,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors have also recently modified their holdings of FATE. Fox Run Management L.L.C. purchased a new stake in Fate Therapeutics during the third quarter worth $25,000. Vanguard Personalized Indexing Management LLC bought a new stake in Fate Therapeutics during the third quarter valued at about $30,000. Epiq Partners LLC purchased a new position in Fate Therapeutics in the fourth quarter valued at about $38,000. Nisa Investment Advisors LLC raised its holdings in Fate Therapeutics by 1,069.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 16,840 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 15,400 shares in the last quarter. Finally, Laurion Capital Management LP lifted its position in shares of Fate Therapeutics by 128.6% during the third quarter. Laurion Capital Management LP now owns 35,173 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 19,787 shares during the last quarter. 97.54% of the stock is currently owned by institutional investors. Fate Therapeutics Trading Down 5.8 % Shares of NASDAQ FATE opened at $3.90 on Monday. The company has a 50 day simple moving average of $5.67 and a two-hundred day simple moving average of $4.84. The stock has a market cap of $443.94 million, a price-to-earnings ratio of -2.03 and a beta of 1.80. Fate Therapeutics, Inc. has a 12 month low of $1.63 and a 12 month high of $8.83. Fate Therapeutics (NASDAQ:FATE – Get Free Report) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.47). The company had revenue of $1.93 million during the quarter, compared to the consensus estimate of $0.80 million. Fate Therapeutics had a negative net margin of 2,933.79% and a negative return on equity of 46.49%. During the same period in the previous year, the firm posted ($0.19) earnings per share. Analysts forecast that Fate Therapeutics, Inc. will post -1.9 EPS for the current year. Analyst Upgrades and Downgrades FATE has been the subject of several recent analyst reports. Oppenheimer reiterated a “market perform” rating on shares of Fate Therapeutics in a research note on Tuesday, February 27th. Wedbush reiterated a “neutral” rating and set a $7.00 price objective on shares of Fate Therapeutics in a report on Monday, May 6th. StockNews.com downgraded Fate Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 10th. Morgan Stanley increased their price target on Fate Therapeutics from $3.00 to $7.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 27th. Finally, Barclays upped their price objective on shares of Fate Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $6.58. Check Out Our Latest Stock Report on Fate Therapeutics Fate Therapeutics Company Profile (Free Report) Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
